NCT05055947已完成不适用
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy
排除标准
- •Patients with contraindication of chemotherapy Pregnant or breast feeding women
结局指标
主要结局
OS
时间窗: April 2019- July 2021
Overall survival
PFS
时间窗: April 2019- July 2021
Progression free survival
次要结局
未报告次要终点
研究者
Yongchang Zhang
HunanPTH
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Adebrelimab + Apatinib in SCLC Maintenance TherapySCLCNCT06475209Tang-Du Hospital60
招募中
不适用
Exploratory study of biomarkers for therapeutic efficacy and immune-related adverse events of immune checkpoint inhibitorsAll cancer types indicated for immune checkpoint inhibitorJPRN-UMIN000043798Kumamoto University400
进行中（未招募）
2 期
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)Non-small Cell Lung Cancer MetastaticLiver MetastasesHepatocellular CarcinomaNCT04563338University Health Network, Toronto36
进行中（未招募）
2 期
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryCancerNCT06754501M.D. Anderson Cancer Center4
已完成
2 期
Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaSmoldering Multiple MyelomaNCT01441973Bristol-Myers Squibb41